Novartis: positive phase II results for rare blood disease
(CercleFinance.com) - Novartis said a mid-stage trial substantially improved hematological response in patients with paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood disease.
In a Phase II study, the investigational oral drug LNP023 demonstrated improvements in hematological response and biomarkers of disease activity in patients with active hemolysis despite treatment with eculizumab, the Swiss company said.
"These new data clearly highlight that LNP023 can control the mechanisms of hemolysis in this disease, and may potentially change the treatment paradigm for PNH," said Prof. Peffault de Latour, one of the principal investigators of the study.
All patients required red blood cell (RBC) transfusions before they started the treatment.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In a Phase II study, the investigational oral drug LNP023 demonstrated improvements in hematological response and biomarkers of disease activity in patients with active hemolysis despite treatment with eculizumab, the Swiss company said.
"These new data clearly highlight that LNP023 can control the mechanisms of hemolysis in this disease, and may potentially change the treatment paradigm for PNH," said Prof. Peffault de Latour, one of the principal investigators of the study.
All patients required red blood cell (RBC) transfusions before they started the treatment.
Copyright (c) 2020 CercleFinance.com. All rights reserved.